ArticleArchives of microbiology2025
Shifting from pro-inflammatory to regulatory: L. reuteri postbiotics modulate IL-17/IL-10 axis in LPS-induced HT-29 IBD model.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic mucosal inflammation and decreased epithelial barrier function are hallmarks of inflammatory bowel disorders (IBDs), partially caused by dysregulated cytokine signaling. Researchers are looking into probiotics and their byproducts, called postbiotics, as safer options for broad immunosuppressants like cyclosporine. This study aimed on investigating the effect of metabolites derived from Lactobacillus reuteri (ATCC 23272) on lipopolysaccharide (LPS)-induced inflammation model of HT-29 epithelial cells. Cell viability (MTT), apoptosis (Annexin V-FITC flow cytometry), cytokine expression (IL-4, IL-10, IL-17), and gene transcription (IL-8, IL-10) were evaluated after treatment of in vitro induced model comparing metabolites with cyclosporine (conventional therapy used for IBD treatment) at different time points. Using a 50% postbiotic solution increased the viability of HT-29 cells (≈ 140%, p < 0.0001) showing no cytotoxicity. In inflamed conditions, IL-17⁺ cells decreased by almost 50% (0.48-fold compared to LPS+, p < 0.0001), although IL-10⁺ cells exhibited a little increase (1.1-fold compared to LPS+, p = 0.0023). By day 5, IL-8 expression was significantly downregulated at the transcriptional level (p = 0.0121), with effects that were stronger than those of cyclosporine (p = 0.0040). In general, L. reuteri metabolites brought back apoptosis, lowered IL-8 and IL-17 levels while sustaining IL-10 increased, thus affecting immunological milieu of the epithelium toward resolution. These results were comparable or even superior to those of cyclosporine, indicative of the stability and safety of postbiotics as good candidates for IBD treatment. Additional research utilizing intestinal organoids and animal models is advised to validate their therapeutic efficacy.
Indexed as
Identifiers
41364271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.